Bioxcel therapeutics regains compliance with nasdaq minimum bid price rule

New haven, conn., feb. 28, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) that the company has regained compliance with the minimum closing bid price requirement under nasdaq listing rule 5550(a)(2).
BTAI Ratings Summary
BTAI Quant Ranking